Neurologic clinical trials - Namenda TAME

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT02118727

CONDITION(S): Amyotrophic Lateral Sclerosis (ALS) - TRIAL: Namenda TAME - Therapy in Amyotrophic Lateral Sclerosis (TAME) Multi-centered double blind, placebo controlled study evaluating the safety and efficacy of memantine at 20mg BID in patients with ALS currently taking riluzole.

Drug

Drug: Memantine, placebo

Trial Type

Interventional

Age Range

18 years or older

Condition

Amyotrophic Lateral Sclerosis (ALS)

Keywords

Amyotrophic Lateral Sclerosis (ALS) | Frontal Temporal Dementia | memantine | riluzole